超越Sedlis标准:宫颈癌复发风险的组织学特异性列线图
本研究基于GOG 49、92、141的辅助分析,纳入715例鳞癌和105例腺癌的I期术后未接受辅助治疗患者,评估不同组织学类型的复发危险因素并构建3年复发风险列线图。结果显示鳞癌与腺癌的复发危险因素不同,组织学特异性列线图可更精准地指导辅助治疗。
要点
- 鳞癌复发危险因素包括LVSI、肿瘤≥4cm及浸润深度,腺癌仅肿瘤≥4cm与复发相关。
- 两种组织学类型中肿瘤大小与LVSI存在交互作用。
- 组织学特异性列线图可线性估计3年复发风险,辅助个体化治疗决策。
核心结论
- 宫颈鳞癌与腺癌的复发危险因素不同,基于鳞癌数据制定的Sedlis标准可能不适用于腺癌。
- 组织学特异性列线图能准确且线性地表示鳞癌和腺癌的复发风险,可为临床辅助治疗提供更精准的工具。
研究设计与样本
- 对GOG 49、92、141三项研究进行辅助分析,纳入I期、手术治疗且未接受新辅助/辅助治疗的患者。
- 共纳入715例鳞癌和105例腺癌患者,采用多因素Cox比例风险模型评估复发独立危险因素并构建3年复发风险列线图。
主要发现
- 鳞癌患者中20%复发,腺癌患者中17%复发。
- 鳞癌中,LVSI(HR 1.58,CI 1.12-2.22)、肿瘤大小≥4cm(HR 2.67,CI 1.67-4.29)、浸润深度中1/3(HR 4.31,CI 1.81-10.26)和深1/3(HR 7.05,CI 2.99-16.64)与复发相关。
- 腺癌中,仅肿瘤大小≥4cm与复发相关(HR 4.69,CI 1.25-17.63)。
- 两种组织学类型中肿瘤大小与LVSI均存在交互作用。
- 鳞癌中浸润深度与复发关联最强(风险16%);腺癌中肿瘤大小在LVSI阴性时风险15%,LVSI阳性时风险25%。
关键数值与推荐
- 鳞癌复发风险因素:LVSI阳性、肿瘤≥4cm、浸润深度中1/3或深1/3。
- 腺癌复发风险因素:肿瘤≥4cm;LVSI阳性时肿瘤≥4cm的复发风险为25%,LVSI阴性时为15%。
临床怎么用
- 临床可依据组织学类型(鳞癌或腺癌)使用特异性列线图评估3年复发风险,指导术后辅助治疗决策。
- 对腺癌患者,肿瘤≥4cm应视为重要复发风险因素,尤其合并LVSI阳性时风险更高。
局限性
- 为回顾性辅助分析,样本量有限(腺癌仅105例)。
- 未报告外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were defined for squamous cell carcinoma (SCC) at an estimated recurrence risk of ≥30%. Our study evaluates and compares risk factors for recurrence for cervical SCC compared with adenocarcinoma (AC) and develops histology-specific nomograms to estimate risk of recurrence and guide adjuvant treatment. METHODS: We performed an ancillary analysis of GOG 49, 92, and 141, and included stage I patients who were surgically managed and received no neoadjuvant/adjuvant therapy. Multivariable Cox proportional hazards models were used to evaluate independent risk factors for recurrence by histology and to generate prognostic histology-specific nomograms for 3-year recurrence risk. RESULTS: We identified 715 patients with SCC and 105 with AC; 20% with SCC and 17% with AC recurred. For SCC, lymphvascular space invasion (LVSI: HR 1.58, CI 1.12-2.22), tumor size (TS ≥4 cm: HR 2.67, CI 1.67-4.29), and depth of invasion (DOI; middle 1/3, HR 4.31, CI 1.81-10.26; deep 1/3, HR 7.05, CI 2.99-16.64) were associated with recurrence. For AC, only TS ≥4 cm, was associated with recurrence (HR 4.69, CI 1.25-17.63). For both histologies, there was an interaction effect between TS and LVSI. For those with SCC, DOI was most associated with recurrence (16% risk); for AC, TS conferred a 15% risk with negative LVSI versus a 25% risk with positive LVSI. CONCLUSIONS: Current treatment standards are based on the Sedlis criteria, specifically derived from data on SCC. However, risk factors for recurrence differ for squamous cell and adenocarcinoma of the cervix. Histology-specific nomograms accurately and linearly represent risk of recurrence for both SCC and AC tumors and may provide a more contemporary and tailored tool for clinicians to base adjuvant treatment recommendations to their patients with cervical cancer.
引用
- Levinson K, Beavis AL, Purdy C, et al. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021. PMID: 34217544. doi:10.1016/j.ygyno.2021.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。